StockData
IBACNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends September 30Also trades as IBACR

IB Acquisition Corp.

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$10.86+0.00 (0.00%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

About IB Acquisition

Services-Commercial Physical & Biological Research, SIC 8731

IB Acquisition Corp. is a blank check company established to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company maintains an opportunistic investment strategy without a restriction to a specific sector, though it focuses on high-growth businesses across fintech, healthcare and life sciences, sports and entertainment, and consumer goods. As an entity with no active operations, it provides prospective acquisition candidates with an alternative path to public markets and growth capital rather than selling direct commercial products or services to typical retail or enterprise end customers.

The company operates from its principal executive offices in Boca Raton, Florida. While organized under the laws of the State of Nevada, it targets potential business combination candidates domiciled across North America, Europe, and Asia, generally seeking prospective partner entities with enterprise values of at least $500 million.

Summary of the business section of IB Acquisition's latest annual report, written by StockData.

Company profile

Company

Legal name
IB Acquisition Corp.
Founded
2020
Headquarters
Boca Raton, FL
Address
2500 N Military Trail, Suite 160-A 33431
Phone
(214) 687-0020
Employees
500, Sep 30, 2025
Industry
Services-Commercial Physical & Biological Research
Incorporated in
Nevada
Fiscal year ends
September 30
Auditor
MaloneBailey LLP, Houston, Texas

Stock & identifiers

Ticker
IBAC
Other tickers
IBACR
Exchange
Nasdaq
IPO date
Mar 27, 2024
Shares outstanding
5M, Aug 14, 2026
Public float
$14.84M, Mar 31, 2025
Filer category
<br>Emerging growth company
SEC CIK
1998781
CUSIP
44934N108
ISIN
US44934N1081
EIN
85-2946784

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

IB Acquisition's leadership is listed in its proxy statement, last filed Sep 4, 2026.

Employees

Headcount reported in annual reports

“● our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; … Our investment strategy is not specific to any sector; however, the management team and board members believe there are compelling investment opportunities in a number of areas including consumer goods, sports and entertainment, and healthcare technology. We anticipate targeting companies domiciled in North America, Europe and Asia, with an ente”

Corporate history

Events identified from SEC filings